顯微鏡的多發血管炎 (MPA) 治療的全球市場:2020-2027年
Global Microscopic Polyangiitis (MPA) Treatment Market - 2020-2027
|顯微鏡的多發血管炎 (MPA) 治療的全球市場:2020-2027年 Global Microscopic Polyangiitis (MPA) Treatment Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
全球顯微鏡的多發血管炎 (MPA) 治療藥市場，主要由於MPA的新治療藥的開發增加及堅固的開發平台藥物而促進成長。由於美國食品藥物管理局(FDA)，歐洲藥品管理局(EMA)，英國醫藥品、醫療產品法規廳(MHRA)等的法規機關，對MPA治療醫藥品的認證持續增加，也更加促進成長。可是，MPA市場成長，由於藥物引起的副作用等幾個要素而受到抑制。
本報告提供全球顯微鏡的多發血管炎 (MPA) 治療藥市場相關調查，市場概要，各市場區隔及各地區的市場規模的預測，主要企業的簡介，競爭情形分析等系統性資訊。
The global microscopic polyangiitis (MPA) treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Microscopic polyangiitis (MPA), known as an ANCA-associated vasculitis is a rare disorder characterized by inflammation of the blood vessels, that restricts the blood flow and damage vital organs and tissues. Some other forms of ANCA-associated vasculitis include eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). MPA mostly affects the small to medium-sized blood vessels, particularly involving the kidneys, lungs, nerves, skin, and joints. It can worsen rapidly, so early diagnosis and treatment are essential to prevent kidney or respiratory damage, or organ failure.
Microscopic polyangiitis can affect both men and women across all ages, but the average age is around 50 and men may get MPA more often. MPA is rare, with prevalence at 1 to 3 cases per 100,000 people in the United States. The incidence is around 2 cases per 100,000 people in the United Kingdom and an estimated 1 case per 100,000 people in Sweden.
MPA is diagnosed by several tests including, blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for diagnosis of red blood cells (RBCs), and imaging procedures such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If these tests are positive for the presence of MPA, biopsy (tissue sample testing) is performed for confirmation of the presence of MPA.
The global microscopic polyangiitis (MPA) treatment market growth is majorly driven by the rising development of new treatments for MPA and robust pipeline drugs. Some of the pipeline drugs for the treatment of microscopic polyangiitis are Abatacept, IFX 1, among others. In July 2018, InflaRx N.V., a German clinical-stage bio-pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatment for MPA is expected to boost the growth of microscopic polyangiitis market over the forecast period.
The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA is further driving the growth of the market. For instance, in October 2018, Genentech received the U.S. Food and Drug Administration (FDA) approval to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis (MPA), who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.
However, the global microscopic polyangiitis market growth is hindered by some of the factors, including side-effects caused by the drugs. Some of the side-effects caused by corticosteroids include skin thinning and intense pain. The monoclonal antibody production involves costly and time-consuming research. Azathioprine involves side effects such as diarrhoea, joint pain, loss of coordination, seizure, and vision changes.
The treatment of microscopic polyangiitis is based on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids such as prednisone used in combination with other medications that suppress the immune system and reduce inflammation. However, even with treatment, MPA is a chronic condition with periods of relapse and remission, so ongoing medical care and monitoring are necessary. Some of the drug available for the treatment of MPA are Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, and others. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab for the treatment of MPA and GPA. (Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation.). Rituximab is expected to gain maximum share over the forecast period (2020-2027).
On the other hand, cyclophosphamide is growing at a significant growth rate over the forecast period. It is a chemotherapy-type drug which blocks the abnormal growth of certain cells in the body, in combination with prednisone. Prednisone is typically started at a high dose and then tapered off slowly. Cyclophosphamide lowers the body's ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications such as mycophenolate mofetil and azathioprine, or methotrexate, a drug commonly used to treat rheumatoid arthritis. Some milder forms of MPA are typically treated with a combination of prednisone and methotrexate.
North America region is dominating the global microscopic polyangiitis (MPA) treatment market accounting for the maximum market share in 2019, due to the increasing development of drugs for the treatment of MPA. In the United States, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and the prevalence is one to three cases per 100,000 population. In September 2019, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients two years of age and older.
On the other hand, Europe microscopic polyangiitis market is projected to grow at a significant CAGR over the forecast period, due to increasing clinical trials and approval of drugs. For instance, Bristol-Myers Squibb Company is conducting phase III clinical trials for Abatacept (Orencia), which is expected to be completed by September 2022. Orencia is a recombinant protein, that inhibits the T lymphocyte activation pathway, thereby suppressing the immune system.
Asia Pacific microscopic polyangiitis market is expected to grow at the fastest CAGR over the forecast period, due to increasing product launches. For instance, in March 2018, Amerigen Pharmaceuticals Ltd., a China-based generic pharmaceutical company, received the US FDA approval for the Abbreviated New Drug Application ('ANDA') for its cyclophosphamide capsules 25mg and 50mg. Cyclophosphamide is an immunosuppressive agent for the treatment of microscopic polyangiitis in combination with corticosteroids.
The microscopic polyangiitis (MPA) treatment market is highly competitive and consists of several major players and emergence of new players in the market. Some of the key players which are contributing to the growth of the market are ChemoCentryx Inc., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), TTY Biopharm Company Ltd, Genentech, Inc., InflaRx N.V., Bristol-Myers Squibb Company, Amerigen Pharmaceuticals Limited, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, which are contributing to the growth of the microscopic polyangiitis (MPA) treatment market globally. For instance,
The global microscopic polyangiitis (MPA) treatment market report would provide an access to an approx. 58 market data table, 54 figures and 250 pages.
LIST NOT EXHAUSTIVE